Zentalis Pharmaceuticals
San Diego, California, United States · Biotechnology, Healthcare, Medical
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clini
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 170
- Industries
- Biotechnology, Healthcare, Medical
- Status
- Public (ZNTL)
- Website
- http://zentalis.com
- Company page
Recent activity at Zentalis Pharmaceuticals
- : SEC 8-K (7.01): Beginning November 9, 2026, Zentalis Pharmaceuticals, Inc. will present information from its Corporate Presentation at various conferences and meetings with investors and analysts. This disclosure relates to the strategic communication of information to stakeholders aimed at enhancing transparency and engagement, which is critical for investor relations. The presentations will incorporate data from the attached press release and corporate presentation, ensuring that stakeholders are informed of the company's recent developments and outlook. This proactive approach indicates the company's commitment to maintaining an open line of communication with the investment community.
- : SEC 8-K (8.01): On August 13, 2026, Zentalis Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc. for the offering of 23,000,000 shares of the Company’s common stock at an offering price of $3.50 per share. The agreement provides the underwriters with a 30-day option to purchase an additional 3,450,000 shares. The net proceeds from this offering are estimated to be approximately $75.1 million, which will be used to fund various corporate activities including clinical trials and regulatory filings. The closing is expected to occur on August 17, 2026, subject to customary closing conditions, demonstrating strategic growth for the Company in its ongoing projects.
- : SEC 8-K (7.01): On August 6, 2026, Zentalis Pharmaceuticals, Inc. announced that their spokespersons would begin presenting information included in the Corporate Presentation (Exhibit 99.2) at various conferences and meetings with investors and analysts. The presentation, aimed at enhancing communication about the company's strategies and performance, outlines critical insights that the company deems valuable for stakeholders. The filing clarifies that the information provided shall not be considered 'filed' under the Securities Exchange Act, thus limiting liability under that section. This proactive engagement strategy suggests a strong emphasis on investor relations following recent corporate developments.
Employee benefit plans
Zentalis Pharmaceuticals files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.
About Zentalis Pharmaceuticals: questions and answers
What does Zentalis Pharmaceuticals do?
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clini
Where is Zentalis Pharmaceuticals headquartered?
Zentalis Pharmaceuticals is headquartered in San Diego, California, United States.
How many employees does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has about 170 employees.
What is the latest news on Zentalis Pharmaceuticals?
On Nov 09, 2026, SEC 8-K (7.01): Beginning November 9, 2026, Zentalis Pharmaceuticals, Inc. will present information from its Corporate Presentation at various conferences and meetings with investors and analysts. This disclosure relates to the strategic communication of information to stakeholders aimed at enhancin
Is Zentalis Pharmaceuticals a public company?
Yes. Zentalis Pharmaceuticals is publicly traded under the ticker ZNTL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy